4DMEDICAL Ltd (4dx) Logo


___:___ · Healthcare

4DX Chart


4DX's Principal Activity is the medical research technology and development of a non‑invasive respiratory imaging solution using four‑dimensional imaging.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -40.87%
vs ASX 200 (1yr) -48.13%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 901 of 2,413
Sector Rank 61 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies RCE / EMV / M7T
EPS -$0.072
DPS $0.00
Book Value Per Share $0.28

Broker Consensus

4DX is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

4DMedical Limited (4DX) is a medical research technology and development of a non‑invasive respiratory imaging solution using four‑dimensional imaging. This four‑dimensional lung imaging technology utilises proven, patented mathematical models and algorithms to convert X‑ray scans into quantitative data to enhance the capacity of physicians to manage patients with respiratory diseases and diseases of the lung. The company is based in Melbourne, Australia and Los Angeles, USA.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Carlton VIC 3053
Website www.4dmedical.com
Registry Link Market Services
Auditor PKF Melbourne Audit & Assurance Pty Ltd
Date Listed 7 Aug 2020

Upcoming Calendar (Forecasted)

Date Event
23/08/2022 Report (Prelim)
22/09/2022 Report (Annual)
27/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Melanie Jaye Leydin Company Secretary Feb 2022
Ms Evonne Maree Collier Non-Executive Director Dec 2021

Ms Evonne Maree Collier

Non-Executive Director

Ms Collier is a professional director and an experienced leader in business scale-up, transformation and digital disruption, and has multinational experience across SaaS, sales and marketing in industries spanning MedTech, FinTech, pharmaceutical/health, eCommerce/Digital and FMCG. Ms Collier has served as non-executive director on various boards since 2011 and currently serves as non-executive director of global SaaS analytics company, Sage Automation, digi-healthtech, Curae Health, SaaS FinTech, Sniip, and Motorama Group Holdings. Ms Collier was previously non-executive director of ASX listed entities 1300Smiles (ASX:ONT) and Vault Intelligence (ASX:VLT).

Mr Bruce Rathie Non-Executive Chairman,Non-Executive Director Dec 2019

Mr Bruce Rathie

Non-Executive Chairman,Non-Executive Director

Mr Rathie is a professional Non Executive Director of 20 years, having completed successful prior careers in law and finance. He is strong in governance. His legal career included being partner of a prominent private law firm, then Senior Corporate Counsel to Robert Holmes a Court's Bell Resources Limited in the 1980s. After completing his MBA in Switzerland, he went into investment banking in 1986 which took him to New York for three years returning to Sydney in 1990. He spent the 1990s as an investment banker in Sydney, the last five as Director Investment Banking and Head of the Industrial Franchise Group at Salomon Brothers and then Salomon Smith Barney where he lead the firm's joint lead manager roles in the privatisations or IPOs of Qantas, Commonwealth Bank and Telstra amongst other major transactions of the day. He has been a professional director since 2000 in roles with ASX listed and unlisted companies predominantly in the financial services, biotechnology and technology sectors. He is currently a Non Executive Director of ASX 200 PolyNovo Limited, Capricorn Society Limited, ASX listed Cettire Limited and Australian Meat Processors Corporation Limited. He is also Chairman of Capricorn Mutual Limited and 4DMedical. Previously, he has been a Non Executive Director of ASX listed companies Netlinkz Limited, Compumedics Limited, Anteo Diagnostics Limited (Chairman), USCOM Limited, Mungana Goldmines Limited and Datadot Technology Limited (Chairman). He also served as an inaugural CSIRO nominated Non Executive Director of Polynovo Biomaterials Pty Ltd when the Polynovo technology was first spun out of the CSIRO in 2004, as with several other CSIRO technology commercialisations and served as chairman of a number of these vehicles

Ms Lilian (Lil) Bianchi Non-Executive Director Dec 2019

Ms Lilian (Lil) Bianchi

Non-Executive Director

Ms Bianchi brings to 4DMedical an invaluable history of experience in technology products and business transformations, helping lead boards to build an agile and robust strategy through expansive growth. She has participated in business transformations for U.S. listed technology companies and risk collaborations across financial risk modelling, climate science and primary industry productivity models. She is an experienced contributor to business transformations for U.S.listed technology companies with technology product expertise with AI and SaaS offerings and has vast international experience in the U.S., Australia, India, Singapore, UK, France, Germany, New Zealand, Italy and Spain. Ms Bianchi's value to the 4DMedical Board of Directors lies in her CEO, board, and senior executive track record in financial services, global listed billion dollar tech corporations, tech start ups, tier 1 management consultancies, public sector organisations, and international research operations. Her governance, strategy and capital raising experience has helped her lead corporations in periods of growth, guiding them in the pivot to stock market listings and international sales. Ms Bianchi is an independent director and is Chair of the Audit and Risk Committee.

Mr John Andrew Livingston Non-Executive Director Mar 2018

Mr John Andrew Livingston

Non-Executive Director

Mr Livingston was previously one of the founding partners of Lake Imaging, subsequently becoming part of Integral Diagnostics Ltd., where Mr Livingston was Chief Executive Officer and Managing Director. Mr Livingston was awarded the AGFA International Award for Development of Digital Imaging Solutions in 2005. He has lectured in Australia and abroad on the digital radiology environment, as well as business strategies and systems within the commercial sector. Mr Livingston has considerable commercial experience, having worked with the team at Lake Imaging and later Integral Diagnostics through acquisitions and the establishment of Greenfield facilities across Australia. During his career at Integral Diagnostics, Mr Livingston lead the group through private equity investment with Advent Partners in 2014 and in 2015 Mr Livingston worked with Advent to list Integral Diagnostics on the ASX. Mr Livingston is a former director of VicWest Community Telco and United Way; a current director at QScan, Comrad Medical Systems and Ballarat Clarendon College (Chairman). Mr Livingston is Chair of the Remuneration and Nomination Committee

Mr Julian Bernard Kingsley Sutton Non-Executive Director Sep 2017

Mr Julian Bernard Kingsley Sutton

Non-Executive Director

Mr Sutton started his career in 1995 as an actuarial analyst for Towers Perrin in Melbourne where he consulted to some of Australia's largest superannuation funds. He later transferred with Towers Perrin to Brussels and then London, where he worked predominantly in an asset consulting capacity. In 2002, Mr Sutton joined Credit Suisse Asset Management in London as an assistant portfolio manager in their Multi Manager team. Driven by strong performance, the team grew assets under management ten fold from GBP50 million to GBP500 million over the following two years. In 2004, Mr Sutton joined Schroders Investment Management as a Senior Portfolio Manager in the Multi Asset team, responsible for the management of a suite of investment funds with assets under management in excess of USD1 billion. These funds were invested on a global basis and had exposure to a broad range of asset classes including private equity, hedge funds, property, commodities, equities, bonds and cash. After seven years with Schroders, Mr Sutton returned to Australia with entrepreneurial ambitions. Mr Sutton established a sales and marketing business that helps best in class international fund management companies establish a presence in the Australian and New Zealand market. Currently, Mr Sutton is responsible for the sales and marketing function of Brown Advisory in Australia. Mr Sutton is a member of the Remuneration and Nomination Committee.

Dr Robert Alan Figlin Non-Executive Director Dec 2016

Dr Robert Alan Figlin

Non-Executive Director

Dr Figlin is the Steven Spielberg Family Chair in Hematology Oncology, Professor of Medicine and Biomedical Sciences, Deputy Director for Cedars Sinai Cancer, and Deputy Director of the Samuel Oschin Comprehensive Cancer Institute. Dr Figlin received his medical degree from the Medical College of Pennsylvania. He completed his residency and chief residency in internal medicine at Cedars Sinai Medical Center and a fellowship in hematology/oncology at the David Geffen School of Medicine at UCLA. He is an Emeritus Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA. Prior to joining Cedars Sinai, Dr Figlin was the Arthur and Rosalie Kaplan Endowed Chair of the Department of Medical Oncology and Therapeutics Research, and the Associate Director for Clinical Research at the City of Hope Comprehensive Cancer Center. Prior to that, Dr Figlin served as the Henry Alvin and Carrie L. Meinhardt Endowed Chair in Urologic Oncology and Professor of Medicine and Urology in the Divisions of Hematology/Oncology and Urologic Oncology at the David Geffen School of Medicine at UCLA. Dr Figlin joined the UCLA faculty as Assistant Professor of Medicine in the Division of Hematology/Oncology and was Co Director of the Jonsson Comprehensive Cancer Center's Oncology Program. He held the post of Medical Director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as Program Director of Solid Tumor Developmental Therapeutics within the Cancer Center. Dr Figlin serves as Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, The Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He has authored over 400 peer reviewed articles, more than 70 book chapters, and has published as editor multiple books in kidney cancer. A nationally recognised leader in genitourinary and thoracic oncology in the United States, Dr Figlin's research focuses on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at Cedars Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership is in developing novel anticancer drugs that avoid the toxicity associated with standard treatments furthers Cedars Sinai's tradition of compassionate patient care

Dr Andreas Fouras Chief Executive Officer,Managing Director Dec 2012

Dr Andreas Fouras

Chief Executive Officer,Managing Director

Mr Fouras started his career in academic research studying experimental fluid dynamics. His early research in wind tunnel quantification placed him as a young leader in the area of imaging (within fluid dynamics) developing a number of new approaches to the imaging of gas and liquid flow. Completing a Masters and PhD, and then rapidly rising to the position of Professor of Mechanical and Aerospace Engineering and Director of the Laboratory for Dynamic Imaging, Mr Fouras was recognised by various accolades from a wide range of premier research bodies including the National Health and Medical Research Council and the American Asthma Foundation. Mr Fouras was able to apply novel concept to clinical use through the development of XV Technology, uniquely measuring airflow within the breathing lungs, at every stage of the breath, with both high spatial and temporal resolution at very low dose. Mr Fouras' research has been documented in over 100 peer reviewed publications and over 40 patents and patent applications. Mr Fouras founded 4DMedical in December 2012 from a desire for his work to reach and positively influence as many people globally as possible. A recognised leader, as evidenced by an Australian Davos Connection Australian Leadership Award (2013), Mr Fouras is now dedicated to applying his business acumen, drive and innovation to the commercialisation of 4DMedical's technologies

Director Transactions

4DX directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
22/03/22 Andreas Fouras Buy +11,277 $0.887 $10,000 On-market trade
07/04/21 Lilian (Lil) Bianchi Issued 3,306 $1.55 $5,124 Participation in share purchase plan
07/04/21 Lusia Guthrie Issued 2,409 $1.55 $3,733 Participation in share purchase plan
07/04/21 Bruce Rathie Issued 9,638 $1.55 $14,938 Participation in share purchase plan

Director Interests

The current holdings of 4DX directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Andreas Fouras 22/03/2022 5,133,720 64,838,000 6,036,693 N/A
Julian Sutton 30/06/2021 297,786 183,014 6,205,162 N/A
Lilian (Lil) Bianchi 30/06/2021 N/A 53,306 N/A N/A
Robert Figlin 30/06/2021 519,943 N/A N/A N/A
John Livingston 30/06/2021 N/A 1,925,352 N/A N/A
Bruce Rathie 30/06/2021 N/A 509,638 N/A N/A
Evonne Collier N/A N/A N/A N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Sep 1, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
National Nominees Limited 16,355,854 7.88%
JP Morgan Nominees Australia Pty Limited 9,127,791 4.40%
Ryder Innovation Fund LP 6,290,475 3.03%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd 6,149,690 2.96%
HSBC Custody Nominees (Australia) Limited 4,821,206 2.32%
BNP Paribas Noms Pty Ltd 4,542,208 2.19%
HSBC Custody Nominees (Australia) Limited A/C 2 2,695,298 1.30%
CS Third Nominees Pty Limited 2,399,067 1.16%
BNP Paribas Nominees Pty Ltd 1,814,406 0.87%
Citicorp Nominees Pty Limited 1,670,998 0.81%
Truebell Capital Pty Ltd 1,258,064 0.61%
FCR Daunt Pty Ltd 1,250,000 0.60%
Jianwen Xiao 1,216,176 0.59%
AAX Pty Ltd 1,200,000 0.58%
Mr Dean Vincent Egan 1,180,905 0.57%
Alltogether Pty Ltd 1,115,000 0.54%
Wal Assets Pty Ltd 1,103,055 0.53%
Lefkios Michael & Helen Michael 1,004,819 0.48%
Harry Maglis & Chrisy Maglis 1,000,000 0.48%
Edward Jerome Burke & Mary Jane Sinobio 1,000,000 0.48%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 0 0 0 0 0 0

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Andreas Fouras 01/09/2021 64,838,000 22.02
Perennial Value Management Limited 01/09/2021 19,894,267 6.76
Velocimetry Consulting Pty Ltd 01/09/2021 87,016,727 29.55

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
19-08-21 Perennial Value Management Limited 3,765,933 5.35 6.76

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
09-08-21 Velocimetry Consulting Pty Ltd 40,273,602 43.2 29.6

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $1.205 30 June
4DX Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.